Five-year stroke rate in women with signs and symptoms of ischemia undergoing coronary angiography: a retrospective study from the NHLBI-sponsored Women’s Ischemia Syndrome Evaluation (WISE)

A Haftbaradaran1, M Zaya1, PK Mehta1, C Shufelt1, G Lentz1, Shivani Dhawan1, J Petersen2, E Handberg2, BD Johnson2, CJ Pepine2, D Leach2, S Long2 and CN Bairey Merz1

1Barbra Streisand Women’s Heart Center, Cedars-Sinai Heart Institute, Los Angeles, CA 90048, USA
2University of Florida, Gainesville, FL, USA
3University of Pittsburgh, Pittsburgh, PA, USA

Corresponding author: C Noel Bairey Merz. Email: noel.baireymerz@cshs.org

Objective
Cardiovascular diseases including coronary artery disease and cerebrovascular disease remain major causes of morbidity, disability and death in most industrialised countries. Mortality from stroke is the fourth leading cause of death in the United States and a leading cause of long-term severe disability.1 Stroke represents a disproportionate percentage of cardiovascular events in women compared to men and inclusion of stroke better predicts risk in women.2-4 Prior Women’s Ischemia Syndrome Evaluation (WISE) studies have determined elevated five-year major adverse cardiac event rates in women with signs and symptoms of ischemia and non-obstructive coronary artery disease, including a relatively high (2.5–5.2%) frequency of stroke. We explored the clinical setting and validation of these stroke events.5 This study was approved by the site’s internal review board and written informed consent was obtained for all subjects.

Design
We conducted a retrospective chart review of self-reported stroke in a single Women’s Ischemia Syndrome Evaluation centre of subjects enrolled 1998–2003.

Setting
All women underwent clinically indicated coronary angiography, which was quantitatively and qualitatively evaluated for the presence and extent of coronary artery disease by the Women’s Ischemia Syndrome Evaluation angiographic core laboratory (obstructive coronary artery disease: ≥50% stenosis, non-obstructive coronary artery disease: ≥20 and <50%, and no coronary artery disease: <20% luminal stenosis in ≥1 epicardial coronary artery). All coronary segments with any visual abnormality (even luminal irregularities) were measured quantitatively with a computer-based edge detection algorithm or electronic calipers.5

Participants
All participants in WISE are women with signs and symptoms of ischemia who underwent a baseline physical examination.4,5 Demographic data, medical history and symptoms were collected. Cardiac risk was assessed using a self-report questionnaire inquiring for cardiac risk factors.

Main outcome measures
The definition of stroke used was a new onset neurological defect of central origin confirmed by brain imaging (CTA or MRI) evidence of cerebral infarction or intracerebral hemorrhage, as diagnosed by the treating physician and medical records. Three physicians separately reviewed medical charts in 2012 for the cases to confirm stroke/TIA history.

Results
Among the 240 subjects enrolled, 61 dropped out or were lost to follow-up and 19 died, leaving 160 available with five-year follow-up. Demographic data of the subjects are shown in Table 1. Overall, 14 subjects reported stroke (9%). Among these 14 subjects, nine had available medical records to review (64%) and
seven (78%) were confirmed to be strokes. For the two women with unconfirmed strokes, one had syncope with a negative stroke evaluation, while the second case had a negative stroke workup in the setting of cirrhosis and liver transplant. Stroke rates were similar in women with and without obstructive coronary artery disease, although underpowered to detect group differences (Figure 1).

### Table 1. Demographics.

| Baseline characteristics          | No stroke (N = 153) | Confirmed stroke (N = 7) | p   |
|-----------------------------------|---------------------|--------------------------|-----|
| Age (yrs ± SD)                    | 57 ± 10             | 53 ± 11                  | 0.35|
| Body mass index (±SD)             | 32 ± 8              | 30 ± 5                   | 0.54|
| Systolic blood pressure (mmHg ± SD)| 134.9 ± 20          | 148.6 ± 37               | 0.36|
| Diastolic blood pressure (mmHg ± SD)| 75.9 ± 11          | 79.5 ± 11                | 0.38|
| Race (%)                          |                     |                          |     |
| African American                  | 19                  | 14                       |     |
| Hispanic                          | 2                   | 0                        |     |
| Caucasian                         | 78                  | 86                       |     |
| Other                             | 1                   | 0                        |     |
| Former smoker (%)                 | 37                  | 29                       | 0.54|
| Current smoker (%)                | 22                  | 43                       | 0.54|
| History of HTN (%)                | 58                  | 57                       | 1   |
| History of dyslipidemia (%)       | 56                  | 100                      | 0.08|
| History of diabetes (%)           | 29                  | 57                       | 0.24|
| Antihypertensive medication (%)   | 44                  | 43                       | 1   |
| Aspirin (%)                       | 57                  | 43                       | 0.53|
| Statin (%)                        | 24                  | 29                       | 1   |

**Figure 1.** Confirmed stroke rates in women with and without obstructive CAD (p = 0.63 across groups).
Conclusions

Among women with signs and symptoms of ischemia undergoing coronary angiography for suspected ischemia, stroke was confirmed in the majority of cases. While stroke was most commonly associated with obstructive coronary artery disease, a relatively high rate was observed in subjects with non-obstructive coronary artery disease. While the current study results may not represent all women with suspected ischemic heart disease, future study should be directed at mechanistic studies and intervention trials aimed at improved understanding of stroke in this population.

Declarations

Competing interests: None declared

Funding: This work was supported by contracts from the National Heart, Lung and Blood Institutes, nos. N01-HV-68161, N01-HV-68162, N01-HV-68163, N01-HV-68164, grants U0164829, U01 HL649141, U01 HL649241, T32HL69751, 1RI03AG032631 from the National Institute on Aging, GCRC grant MO1-RR00425 from the National Center for Research Resources and grants from the Gustavus and Louis Pfeiffer Research Foundation, Danville, NJ, The Women's Guild of Cedars-Sinai Medical Center, Los Angeles, CA, The Ladies Hospital Aid Society of Western Pennsylvania, Pittsburgh, PA, and QMED, Inc., Laurence Harbor, NJ, the Edythe L. Broad Women's Heart Research Fellowship, Cedars-Sinai Medical Center, Los Angeles, California, the Barbra Streisand Women's Cardiovascular Research and Education Program, Cedars-Sinai Medical Center, Los Angeles, and the Linda Joy Pollin Women's Heart Health Program, Cedars-Sinai Medical Center, Los Angeles.

Ethical approval: All participants provided written informed consent, and all participating sites obtained Institutional Review Board approval.

Guarantor: NBM

Contributorship: AH coordinated the data analysis and wrote the first draft and finalized the manuscript; MZ participated in the analysis and writing and approved the final manuscript; CS participated in the analysis and writing and approved the final manuscript; GL participated in the analysis and writing and approved the final manuscript; SD participated in the analysis and writing and approved the final manuscript; JP participated in the analysis and writing and approved the final manuscript; EH participated in the analysis and writing and approved the final manuscript; BDJ participated in the analysis and writing and approved the final manuscript; CJM participated in the analysis and writing and approved the final manuscript; SL participated in the analysis and writing and approved the final manuscript and obtained the funding; DL participated in the analysis and writing and approved the final manuscript; SL participated in the analysis and writing and approved the final manuscript and obtained the funding.

Acknowledgements: None

Provenance: Not commissioned; peer-reviewed by Farhan Shahid

References

1. CDC, http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6120a5.htm (accessed 27 February 2015).
2. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. American Heart Association Statistics C, Stroke Statistics S. Heart disease and stroke statistics–2013 update: A report from the American heart association. Circulation 2013; 127: e6–e245.
3. Goff DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2013; doi.10.1161/1101.cir.0000437741.0000448606.0000437798.
4. Muntner P, Colantonio LD, Cushman M, Goff DC Jr, et al. Validation of the Atherosclerotic Cardiovascular Disease Pooled Cohort Risk Equations. JAMA 2014. doi: 10.1001/jama.2014.2630.
5. Gulati MG, Cooper RM, McClure C, Johnson BD, Shaw LJ, Handberg EM, et al. Adverse Cardiovascular Outcomes In Women with Nonobstructive Coronary Artery Disease: A Report From The National Institutes of Health-National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study and The St. James Women Take Heart (WTH) Project. Archives Internal Medicine 2009; 169(9): 843–50.